发明公开
EP3984523A1 CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS THEREOF FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
审中-公开
基本信息:
- 专利标题： CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS THEREOF FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
- 申请号：EP21213854.9 申请日：2019-12-06
- 公开(公告)号：EP3984523A1 公开(公告)日：2022-04-20
- 发明人： FARBER, Robert H. , LOEWEN, Gordon Raphael , ZHANG, Xiaoping , GIRI, Nagdeep , CHAN, Jean L. , STIRN, Scott , SAYERS, Brian , TAYLOR, Graeme , COSTA, Christina Marie , PARKS, Stacy , VICKERY, Anthony D. , DOWNING, Kristie M. , IYOHA, Kingsley , NGWENYA-JONES, Ayanda , CHARLIER, Anne , MEHTON, Gurvinder Singh
- 申请人： Neurocrine Biosciences, Inc. , Sanofi
- 申请人地址： US San Diego, California 92130 12780 El Camino Real; FR 75008 Paris 54 Rue de la Boetie
- 代理机构： Mewburn Ellis LLP
- 优先权： US201962816674 P 20190311
- 主分类号： A61K9/00
- IPC分类号： A61K9/00 ; A61K31/395 ; A61K31/426 ; A61K31/573 ; A61P5/00
摘要：
Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Formula I), or a pharmaceutically acceptable salt thereof. Further provided are pharmaceutical formulations and solid forms of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, and their use in the treatment of congenital adrenal hyperplasia (CAH).
IPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K9/00 | 以特殊物理形状为特征的医药配制品 |